33 results about "Bitter taste receptors" patented technology

Provided herein are methods for treating conditions associated with a chemosensory receptor, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a chemosensory receptor ligand, such as a bitter receptor ligand. Also provided herein are chemosensory receptor ligand compositions, including bitter receptor ligand compositions, and methods for the preparation thereof for use in the methods of the present invention. Also provided herein are compositions comprising metformin and salts thereof and methods of use.

Isolated nucleic acids encoding T2R76 polypeptides, recombinantly expressed T2R76 polypeptides, heterologous expression systems for recombinant expression of T2R76 polypeptides, assay methods employing the same, and methods for altering taste perception via administration of a T2R76 modulator. These T22R76 polypeptides can be expressed alone or co-expressed with another T2R polypeptide, preferably a different human T2R polypeptide. These T2R76 polypeptides specifcally respond to bitter ligands including brucine and propylthiouracil (PROP) and therefore can be used in assays that identify compounds that modulate, preferably block bitter taste.

The invention discloses a sweetening agent compound composition capable of keeping the flavor of momordica grosvenori. The sweetening agent compound composition is prepared from the following raw materials: a momordica grosvenori sweetening agent, white dextrin, a bitterness inhibitor and a functional extract, wherein the bitterness inhibitor comprises adenosine monophosphate, ferulic acid, phosphatidic acid, tannic acid and zinc lactate; the functional natural extract comprises one or a combination of more selected from the group consisting of a honeysuckle extract, a roselle extract, a mulberry leaf extract and a coix seed extract. According to the invention, the compound raw materials and a bitter substance are competitively bonded at the bitter taste acceptor sites of tongue cells, sothe stimuli of bitter taste to the tongue is greatly reduced, and the bitter taste of the momordica grosvenori sweetening agent to the oral cavity can be effectively masked. Moreover, by adding the functional extract, the bitter taste is inhibited, the special sweetness of momordica grosvenori is not influenced and shielded, and the special flavor and taste of a momordica grosvenori beverage are maintained; so the application scope and fields of the momordica grosvenori sweetening agent are expanded, and the product value of the momordica grosvenori sweetening agent is improved.

This invention provides isolated nucleic acid and amino acid sequences of gastrointestinal endocrine cell specific G-protein coupled receptors, methods of detecting such receptors, and methods of screening for ligands of such receptors. Furthermore, this invention demonstrates that SrC-1 enteroendocrine cells express multiple bitter taste receptors as well as a-subunits of G proteins that mediate taste signal transduction and respond to bitter taste compounds initiating changes in intracellular calcium concentration. Given that at present there are no cultured cell model system to determine the functional effects of taste receptor-mediated signaling, our findings identify STC-1 cells as a cell model for studying taste-mediated signal transduction.

The invention belongs to the technical field of daily cosmetics, and discloses a composition for removing acnes and repairing a skin barrier, and a preparation method and application of the composition. The composition comprises the following ingredients in parts by weight: 0.5-5 parts of colloidal sulfur, 1-5 parts of plankton extracts and 1-6 parts of humulus lupulus extracts. The invention discovers that the colloidal sulfur, the plankton extracts and the humulus lupulus extracts have a synergistic effect on the aspects of an anti-inflammatory effect, an antibacterial effect, inhibition of 5 [alpha]-reductase activity and bitter receptor activation. Cosmetics prepared from the composition disclosed by the invention have a good acne removing effect, do not irritate the skin, are high in safety and can enhance the skin barrier.

TAS2R46 was identified as a dextromethorphan-binding bitter taste receptor. Novel methods to identify modulators and in particular inhibitors to the bitter taste of dextromethorphan are provided.

The invention discloses an application of flufenamic acid as an effective component in preparation of an airway smooth muscle relaxation agent. Experiments reveal for the first time that a compound (CID: 3371) can activate bitter taste receptors and strongly relax airway smooth muscle cells, and the relaxation degree of the compound is close to that of isoproterenol and salbutamol; and it is prompted that the compound (CID: 3371) can be used for preparing an airway smooth muscle relaxation medicine and also can be used for preparing the airway smooth muscle relaxation agent, so that the compound is used for asthma, chronic obstructive pulmonary diseases and the like, and has a wide application prospect.

The invention particularly relates to an active peptide with a bitterness blocking effect. The amino acid sequence of the active peptide is Asp-Asp-Asn-Lys (DDNK). The invention provides an active peptide with a bitterness blocking effect, which can be effectively combined with a bitterness receptor T2R14, has a continuous and stable masking effect on bitterness substances, and has the outstanding advantages of safety, non-toxic and side effects, easy absorption, industrialization and the like. The active peptide DDNK can be used in food, medicines and health care products with bitterness, and has wide application prospects and very important significance.

The invention relates to a bitter receptor agonist and application thereof in prevention and treatment of SARS-CoV-2 related infectious diseases. Specifically, the invention relates to application of a bitter receptor stimulant as a 2019 novel coronavirus (SARS-CoV-2) inhibitor in preparation of medicines for treating and/or preventing and relieving related diseases such as respiratory tract infection and pneumonia caused by 2019 novel coronavirus infection.

The invention relates to the field of medicine, in particular to an application of quinine and pharmaceutically acceptable salts thereof to preparation of a drug for treating AD (atopic dermatitis) and the drug for treating AD. A mouse model of AD is established by an embodiment, a skin lesion region of a mouse is smeared with a physiological saline solution of quinine, and the skin lesion is found to be obviously reduced. Further research shows that quinine can obviously reduce the pathological injury of the mouse, activate expression of a bitter taste receptor and silk polymerization protein, inhibit IgE in blood of the mouse and secretion of cytokines such as IL-1beta, IL-4, IL-5, IL-13 and IL-33 in skin lesion tissue, and thus, improve the skin condition, enhance the skin barrier function, inhibit occurrence of allergic reaction, relieve skin damage caused by immune reaction, and play a safe and effective role in treating the skin damage caused by AD. The invention expands medicalapplications of quinine and provides a new direction for treatment of AD.

The invention provides a levofloxacin oral administration solution and a preparation method thereof. The levofloxacin oral administration solution is prepared from levofloxacin, corrigents, a pH regulating agent and a solvent, wherein the content of the levofloxacin is 2.5g/100ml, the pH regulating agent is (5mL to 7mL) to 100mL of the using consumption of hydrochloric acid; the corrigent is a mixture of sucrose and saccharin sodium, the content of the sucrose is 48g/100mL to 58g/100mL, and the content of the saccharin sodium is 0.2g/100mL to 0.6g/100mL; and the solvent is a mixture of glycerol, propylene glycol and purified water. The levofloxacin oral administration solution disclosed by the invention adopts the corrigents including the sucrose and the saccharin sodium, and due to cooperation between the two corrigents, the bitter taste of the levofloxacin oral administration solution can be reduced; and because competitive combination of the contained flavor masking agents includingalanine and taurine and the bitter taste receptor in an oral cavity, the bitter taste of levofloxacin can be further reduced, so that the levofloxacin oral administration solution has a better taste;and due to the contained beta-carotene, the photosensitivity adverse effect caused by the levofloxacin can be reduced, and the safety of a preparation is improved.

The invention relates to new use of piperine and application of the piperine in preparation of an agonist of a human bitter receptor 14 subtype (hTAS2R14). The piperine can be used for increasing an mRNA level and protein expression of the hTAS2R14 in enteroendocrine cell cells Caco-2, increasing protein expression of downstream phospholipase C beta 2 and transient receptor potential ion channel protein M5, and increasing mobilization of intracellular calcium, and then, the gene expression of a glucagon-like peptide 1 (GLP-1) precursor proglucagon and the secretion of the GLP-1 are improved. The hTAS2R14 agonist 6-methoxyflavone does not weaken the mobilization effect of the piperine on the intracellular calcium, but promotes the mobilization of the piperine on the intracellular calcium. A G beta gamma subunit inhibitor of the G protein coupled with the hTAS2R14 obviously weakens the secretion of the piperine to the GLP-1, and the phospholipase C beta 2 inhibitor obviously weakens the secretion of the piperine to the GLP-1. The research shows that the piperine is an efficient agonist of the hTAS2R14.